SMART ART研究
南アフリカにおけるARTデリバリーのためのスケーラブルな介入の連続複数割り当て無作為化試験:SMART ART研究
The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with detectable viral load and/or not engaged in care.The types of differentiated service delivery (DSD) that will be examined in this study are incentives, community-based ART, and home delivery. The study plans to enroll up to 900 participants-people living with HIV and who are eligible for ART and living in KwaZulu-Natal, South Africa. The study aims to maximize the proportion of ART eligible persons living with HIV who achieve viral suppression at 18 months. The study will also evaluate the preferences of clients and providers for differentiated service delivery, and evaluate the cost effectiveness of adaptive HIV treatment for those who are not engaged in care.
調査の概要
状態
詳細な説明
Of the 8 million people in South Africa living with HIV, only 56% are on antiretroviral therapy (ART), and 45% are virally suppressed, substantially below the UNAIDS goal of 73%. Detectable viral load results in HIV-associated morbidity and mortality, and HIV transmission. Patient barriers to care, such as missed wages, transport costs, and long wait times for clinic visits and ART refills, are associated with detectable viral load. HIV differentiated service delivery (DSD) has simplified ART delivery: incentives, multi-month scripts, fast-track ART, and community or home ART delivery motivate clients, reduce the frequency of clinic visits, and decongest clinics. DSD is standard for clients who achieve viral suppression and engage in care; however, DSD needs adaptation to serve clients who are not succeeding. Indeed, persons who are not engaged in care arguably need simplified, client-centered approaches even more than those who can successfully engage.
A suite of adaptive DSD strategies, including incentives strategies, community-based ART, and home delivery, have been tested among stable clients with viral suppression. Lottery incentives effectively change short-term behavior, increasing ART initiation.Community-based and home ART delivery increase ART coverage and simplify ART access overcoming clinic barriers11. For stable clients, these DSD activities are as effective as clinic-based care in terms of achieving and maintaining viral suppression, although among stable clients they have not shown superiority in viral suppression or cost savings. In contrast, DSD has the potential to improve rates of viral suppression and retention in care and save costs among persons not engaged in care. There is great potential that DSD systems can be client-responsive and system-efficient for subgroups requiring additional services, matching services with client needs. A sequential, comprehensive package of DSD approaches, with each step increasing the intensity of service provision - adaptive DSD - has not been tested to determine the proportion and characteristics of persons who would achieve viral suppression and retention in care and to estimate the cost-effectiveness and budget impact.
To increase population level viral suppression, persons with detectable viral load need responsive DSD interventions. A Sequential Multiple Assignment Randomized Trial (SMART) design facilitates evaluation of a stepped, adaptive approach to achieving viral suppression with 'right-sized' interventions. The investigators are an experienced team and propose to build on the strong partnerships to sequentially test adaptive DSD strategies for persons with detectable viral load and/or not engaged in care: incentives, community-based ART, and home delivery. As the Center for Community Based Research, the investigators maintain strong connections with stakeholders including department of health, traditional leaders and ward counsellors throughout the Greater Edendale Area (GEA) and the Vulindlela sub-district of the uMgungundlovu District Municipality. Due to the size of the recruitment target, this work will centre around the Caluza clinic but will extend into other parts of GEA and sub-district of Vulindlela over the course of recruitment. The aim is to identify the most effective and efficient HIV care delivery strategies.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
KwaZulu-Natal
-
Sweetwaters、KwaZulu-Natal、南アフリカ
- Human Sciences Research Council Sweetwaters
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Must be 18 years or older
- Able and willing to provide informed consent for study procedures
- Must self report that they will reside in the study community for the duration of follow-up
- Living with HIV and eligible for ART by national guidelines, have a detectable viral load greater than the lower limit of detection and/or not engaged in care, and are stable clinically (CD4>100 cells, no moderate/severe screening laboratory abnormalities for kidney function i.e. eGFR >50 mL/min/1.73m2, not receiving treatment for active tuberculosis or other opportunistic infections).
Exclusion Criteria:
- There are no separate exclusion criteria.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Best clinic practices
Participants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm) |
|
|
実験的:Best clinic practices plus lottery incentives
Participants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm) |
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART |
|
実験的:Randomized from best clinic practices to smart lockers
Second randomization into community ART through the use of smart lockers |
Decentralized ART refills and monitoring, adherence support Continue with best clinic practices |
|
実験的:Randomized from best clinic practices to home delivery
Second randomization into home ART delivery |
Continue with best clinic practices Home ART refill and monitoring, adherence support |
|
実験的:Randomized from best clinic practices plus lottery incentives to smart lockers
Second randomization into community ART through the use of smart lockers |
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART Decentralized ART refills and monitoring, adherence support |
|
実験的:Randomized from best clinic practices plus lottery incentives to home delivery
Second randomization into home ART delivery |
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART Home ART refill and monitoring, adherence support |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Viral suppression at 18 months
時間枠:18 months
|
The primary outcome is viral suppression at 18 months among the combined group of persons living with HIV who have detectable viral load and persons not engaged in care at enrollment. |
18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Retention in Care
時間枠:12 months
|
The proportion of clinical visits and medication refills missed over the last 12 months of the intervention |
12 months
|
|
Time to ART initiation
時間枠:6 months
|
Time to antiretroviral therapy initiation |
6 months
|
|
Engagement in care
時間枠:18 months
|
Proportion of people who are virally suppressed in each intervention arm |
18 months
|
|
Comparison to viral suppression and retention outcomes from similar local clinics
時間枠:18 months
|
Proportion of individuals who are virally suppressed who are engaged in care in intervention arms compared to local clinics |
18 months
|
協力者と研究者
捜査官
- 主任研究者:Ruanne V Barnabas, DPhil、University of Washington
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2022P001129
- R01MH124465 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。